Working… Menu
Trial record 1 of 1 for:    go-colitis
Previous Study | Return to List | Next Study

Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032) (GO-COLITIS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02092285
Recruitment Status : Completed
First Posted : March 20, 2014
Results First Posted : October 13, 2017
Last Update Posted : March 15, 2019
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
The primary objective of this study is to evaluate the efficacy of golimumab in maintaining a clinical response in participants with moderate-to-severe ulcerative colitis.

Condition or disease Intervention/treatment Phase
Ulcerative Colitis Drug: Golimumab Phase 4

Detailed Description:
This study consists of a 1 week screening period, a 54 week treatment period, and a 12 week follow-up period, requiring a total of 7 trial site visits: Visit 1(screening visit, Week -1), Visit 2 (enrollment visit, Day 0), Visit 3 (Week 2), Visit 4 (Week 6), Visit 5 (Week 30) and Visit 6 (Week 54) and Visit 7 (follow-up visit, Week 66).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 205 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Golimumab: A Phase 4, UK, Open Label, Single Arm Study on Its Utilization and Impact in Ulcerative Colitis
Actual Study Start Date : May 9, 2014
Actual Primary Completion Date : May 25, 2016
Actual Study Completion Date : May 25, 2016

Resource links provided by the National Library of Medicine

Drug Information available for: Golimumab

Arm Intervention/treatment
Experimental: Golimumab
The first induction dose of subcutaneous (SC) golimumab 200 mg was administered at Day 0. The second induction dose of SC golimumab 100 mg was administered two weeks later at Week 2. Responders at Week 6 received a maintenance dose of golimumab (50 mg for participants with a body weight <80 kg or 100 mg for participants with a body weight ≥80 kg) every 4 weeks during the Maintenance Phase for 48 weeks, yielding a total of 54 weeks treatment.
Drug: Golimumab
50mg or 100mg solution for injection; subcutaneous injection
Other Name: Simponi®

Primary Outcome Measures :
  1. Percentage of Participants Meeting Partial Mayo Score Response Criteria Through Week 54 [ Time Frame: Baseline (Week 0), Week 6, Week 30, Week 54 ]
    The Partial Mayo Score (Mayo Score without endoscopy) measures severity of ulcerative colitis. Three sub-scores for stool frequency, rectal bleeding, and physician's global assessment are each graded from 0 to 3 with higher scores indicating more severe disease. Individual sub-scores are then summed to provide the total score ranging from 0 (normal or inactive disease) to 9 (severe disease). Clinical response is defined as a decrease in PMS of ≥2 points and ≥30% from baseline, plus either a decrease in rectal bleeding subscore of ≥1 point or an absolute rectal bleeding subscore of ≤1. In this outcome measure, the percentage of participants starting treatment at the start of the Induction Phase (Baseline) who obtained clinical response by the end of the Induction Phase (i.e., by Week 6) and maintained clinical response through Week 54 (i.e., had positive clinical responses at both Weeks 30 and 54) are estimated.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of ulcerative colitis for at least 3 months with moderate-to-severe disease at enrollment.
  • Has a rectal bleeding subscore of 1 or more at baseline.
  • No evidence of active, or latent, or inadequately treated infection with Mycobacterium tuberculosis (TB).
  • Must be eligible to start golimumab treatment according to the summary of product characteristics.
  • Must be naïve to anti-tumor necrosis factor (anti-TNF) therapy.
  • Women of childbearing potential or men capable of fathering children must agree to use adequate birth control measures (eg, abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, implant, surgical sterilization).
  • Women of childbearing potential must test negative for pregnancy at screening.
  • Any prior azathioprine / 6-mercaptopurine use was initiated at least 12 weeks prior to enrollment with either stable dosing or discontinued treatment for the 4 weeks immediately prior to enrollment.

Exclusion Criteria:

  • Clinical signs of ischaemic colitis, fulminant colitis or toxic megacolon.
  • Has evidence of pathogenic bowel infection.
  • Has a diagnosis of indeterminate colitis, or clinical findings suggestive of Crohn's disease.
  • Has had surgery as a treatment for ulcerative colitis, or is likely to require surgery.
  • Has ulcerative colitis which is confined to a proctitis (distal 15 cm or less).
  • Has a current or recent history of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiac, or neurological disease.
  • Has a current immunization with any live virus vaccine or history of immunization with any live virus vaccine within 3 months of baseline.
  • Pregnant or lactating, or planning pregnancy while enrolled in the study.
  • Has received agents that deplete B or T cells (eg, rituximab or alemtuzumab) within 12 months prior to study inclusion, or continue to manifest depletion of B or T cells more than 12 months after completion of therapy with lymphocyte-depleting agents.
  • Has received cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil (MMF) within 8 weeks prior to study inclusion.
  • Has used any investigational drugs within 30 days of Screening.
  • Has a known hypersensitivity to human immunoglobulin proteins or other components of golimumab.
  • Has received methotrexate within 12 weeks prior to enrollment
  • Has received rectal corticosteroids or rectal 5-aminosalicylic acid (5-ASA) compounds within 2 weeks prior to enrollment (may be commenced if required after Week 6 in the study)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02092285

Layout table for location information
United Kingdom
Merck Sharp & Dohme Ltd.
Hoddesdon, United Kingdom
Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Layout table for investigator information
Study Director: Medical Director Merck Sharp & Dohme Corp.
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT02092285    
Other Study ID Numbers: 8259-032
2013-004583-56 ( EudraCT Number )
First Posted: March 20, 2014    Key Record Dates
Results First Posted: October 13, 2017
Last Update Posted: March 15, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Colitis, Ulcerative
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Pathologic Processes
Inflammatory Bowel Diseases